Taken together, our study suggests that JOA may be a lead compound to potentially overcome the limitations of BCR-ABL targeted CML therapy by inhibition of BCR-ABL/c-MYC signaling. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.